Across the globe, since 1975, the problem of obesity has approximately tripled. More than 1.9 billion adults in 2016, who were 18 years and older were over heavy. Of these over 650 million were heavy. A heavy individual is at a sophisticated risk of underdeveloped chronic diseases such as breast cancer, colon cancer, endometrial cancer, type 2 diabetes, musculoskeletal syndromes and cardiovascular diseases. Whereas, the anti-obesity drugs support in decreasing the body mass either by plummeting the hunger or growing the consumption of calories. The significant rise in the prevalence of the obesity across the globe is a foremost aspect fueling the market growth. It principally owes of erroneous eating habits and summarily varying administration of individual. The effective rise in the assimilation of unhealthy food along with the shortage of exercises is intensifying the commonness rate of the obesity around the globe.
Additionally, the basic functions like decreasing the intake of unhealthy diet and indoctrinating workout are not greatly effective, and the medical devices like intragastric balloon and bariatric surgery are effectively costly and have great complications. This represents that there is a broad difference for the treatment of obesity. This unmet requirement is fueling the market for the anti-obesity drugs market. Furthermore, the potential players in the market of anti-obesity drugs are playing an effective role while increasing the insight of healthcare market and investing the high amount of money in the infrastructure.
According to the report analysis, ‘Global Anti-Obesity Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023’ states that there are numerous effective players in the market which presently performing for leading the fastest market growth and registering the high value of market share across the globe during the short span of time while increasing the prevalence of obesity, spreading the side effects of unhealthy lifestyles, increasing awareness of fitness and investing the sufficient amount of money in the advancement of technology includes F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the several other prominent vendors.
The Global Anti-Obesity Drugs Market is predicted to observe an effective CAGR of 20.9% during the forecast period of 2017-2023. Whereas, Novo Nordisk, a modernizer of the drugs in the obesity market, innovated Saxenda in all the mainstream markets with a sophisticated dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was earliest established for the type 2 diabetes as Victoza. The Dual therapy for obesity and type 2 diabetes is the modern trend in the market. Hence, the immense pharmaceutical corporates, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk approach of utilizing diabetes drugs to pleasure the obesity interrelated problematic. This supports the diabetes market players to welcome the plumpness market. J&J is proposed to welcome the marketplace for the preparation anti-obesity drugs without further investing in the enhancement of novel fragments.
Moreover, based on the region, the market of anti-obesity is sectored across the globe which majorly involves North America, Europe, Asia Pacific, and Rest of the World (RoW). Whereas, the North America is the foremost region for the anti-obesity drugs market growth followed by Europe. Asia Pacific and RoW are set to be the developing regions. India and China are set to be the most beautiful destinations owing to the enormous untapped market. Therefore, in the near years, it is predicted that the market of anti-obesity drugs will augment across the globe more effectively over the decades.
For more information on the research report, refer to below link:-
Global Anti Obesity Drugs Market
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
